Dong, Shu-Jie <br/><br/>
Cost-effectiveness of Dabigatran Compared With Rivaroxaban for Prevention of Stroke and Systemic Embolism in Patients With Atrial Fibrillation in China.  [electronic resource] 

 -  Clinical therapeutics  01 2020 
 - 144-156.e1 p.  digital 
<br/><br/> Publication Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1879-114X 
<br/><br/><label>Standard No.: </label>10.1016/j.clinthera.2019.11.011  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aged<br/>Anticoagulants--economics<br/>Atrial Fibrillation--drug therapy<br/>China<br/>Cost-Benefit Analysis<br/>Dabigatran--economics<br/>Embolism--prevention & control<br/>Female<br/>Humans<br/>Male<br/>Markov Chains<br/>Models, Economic<br/>Quality-Adjusted Life Years<br/>Rivaroxaban--economics<br/>Stroke--prevention & control<br/>Treatment Outcome